Models of hematopoietic malignancies: chronic myeloid leukemia

Studies of the molecular mechanisms in the pathogenesis of chronic myeloid leukemia (CML) using various models have contributed greatly to the development of targeted therapies of CML. However, although remarkably effective, selected BCR-ABL tyrosine kinase inhibitors appear not to be sufficient to cure CML. Here, we review the CML disease models currently available for the further elucidation of the mechanism of CML and for the development and testing of novel therapies for CML.

Section editors:Nikolina Vlatovic – University of Liverpool, Liverpool, UKMark T. Boyd – University of Liverpool, Liverpool, UK